Our company Representative Director President and CEO Fuminori Yoshida 's book "A 1/30,000 Miracle: A Drug Discovery Venture Tackling Underserved Therapeutic Areas" was published by Gentosha on August 25, 2025.

There are still many "Underserved Therapeutic Areas" in the medical world. These are rare disease patients who have been left behind by advances in treatment technology and the development of new drugs, desperately waiting for help. Determined to fill these gaps, Yoshida gave up his position as president of a major global pharmaceutical company to found SymBio Pharmaceuticals. Taking on these uncharted Underserved Therapeutic Areas, where risks are high and most pharmaceutical companies are hesitant to enter, proved far more difficult than initially expected. However, by continually implementing measures to overcome these challenges, the company overcame the obstacles and is now on the verge of realizing its founding dream of expanding into a global business.
We obtained new drug approval for the anti-cancer drug TREAKISYM just five years after its introduction. Since then, we have continued to expand its applications, and in fiscal 2021, we established our own sales network, achieving new drug sales of 10 billion yen and achieving profitability. Furthermore, we are currently working with world-class research institutions to develop the groundbreaking new drug brincidofovir. With broad spectrum and high antiviral activity, as well as anti-cancer activity, brincidofovir 's potential as a game-changer is immeasurable. We will first focus our business on viral infections, including adenovirus infections after hematopoietic stem cell transplantation, and blood and solid cancers. Furthermore, we will focus our management resources on three therapeutic areas: viral-induced neurodegenerative diseases, which are expected to become a problem in an aging society, and aim to become a global specialty pharmaceutical company by 2030.
How can a miracle be achieved when working on a new drug development project with a one in 30,000 chance of success? While many venture companies fall into the "valley of death" halfway through, how has this business, founded from scratch, grown over the course of 20 years, and now embarked on a second founding and global expansion? This book explores the practical power of the "aspiration" that underpins the business, while cherishing the "connections" that connect people.
Starting a business from scratch, then relaunching it as a global specialty pharmaceutical company. This dynamism is the result of SymBio 's "magic formula," which solidifies the business model that was established as our founding philosophy.
Learning about the origins of SymBio Pharmaceuticals and its management methods through this book will provide insights for many drug discovery businesses and will also be a catalyst for the development and success of various startups that will shape Japan's future.

(Japanese only) Fuminori Yoshida, Representative Director and CEO, published a book titled "人と社会を幸せにする仕事 (Jobs that make people and society happy)" on February 13, 2014 by Gentosha.
Yoshida wants to challenge the "Underserved Therapeutic Areas" where major pharmaceutical companies have avoided developing new drugs for reasons such as the small number of patients and the lack of profitability, and to deliver new drugs to suffering patients as soon as possible. With this strong “will” as the driving force, he started a pharmaceutical company from scratch.
This book traces the path from the founding of SymBio Pharmaceuticals in 2005 to the present, and describes the many joys and learnings experienced through starting a business from scratch, as well as new management ideas and business models that society will need in the future. It describes how the company should be.
This book is a must read not only for those who are currently at the forefront of corporate management, but also for those who aim to start a business.